1. Home
  2. AEF vs TENX Comparison

AEF vs TENX Comparison

Compare AEF & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AEF

abrdn Emerging Markets Equity Income Fund Inc.

N/A

Current Price

$9.61

Market Cap

315.9M

Sector

Finance

ML Signal

N/A

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

N/A

Current Price

$10.99

Market Cap

317.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AEF
TENX
Founded
1989
1967
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
315.9M
317.8M
IPO Year
N/A
2001

Fundamental Metrics

Financial Performance
Metric
AEF
TENX
Price
$9.61
$10.99
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$29.67
AVG Volume (30 Days)
140.7K
629.4K
Earning Date
01-01-0001
05-15-2026
Dividend Yield
7.13%
N/A
EPS Growth
N/A
N/A
EPS
0.57
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$17.25
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.51
$5.34
52 Week High
$10.14
$18.38

Technical Indicators

Market Signals
Indicator
AEF
TENX
Relative Strength Index (RSI) 54.14 36.53
Support Level $6.19 $10.87
Resistance Level $9.99 $14.15
Average True Range (ATR) 0.25 0.70
MACD -0.01 -0.04
Stochastic Oscillator 60.30 9.75

Price Performance

Historical Comparison
AEF
TENX

About AEF abrdn Emerging Markets Equity Income Fund Inc.

ABERDEEN EMERGING MARKETS EQUITY INCOME FUND, INC. is a closed-end investment company. The Fund's investment objective is to seek to provide both current income and long-term capital appreciation. The Fund invests in a range of sectors, including financials, consumer staples, utilities, consumer discretionary, materials, energy, information technology, private equity, communication services, healthcare, real estate, and industrials.

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

Share on Social Networks: